Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 10
2003 12
2004 9
2005 9
2006 8
2007 13
2008 8
2009 8
2010 9
2011 9
2012 4
2013 5
2014 7
2015 6
2016 2
2017 4
2018 5
2019 2
2020 5
2021 4
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men.
Mahaveer Chand N, Tekumalla PK, Rosenberg MT, Dobi A, Ali A, Miller GM, Aristizabal-Henao JJ, Granger E, Freedland SJ, Kellogg MD, Srivastava S, McLeod DG, Narain NR, Kiebish MA. Mahaveer Chand N, et al. Among authors: mcleod dg. Cancers (Basel). 2024 Feb 8;16(4):712. doi: 10.3390/cancers16040712. Cancers (Basel). 2024. PMID: 38398103 Free PMC article.
Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression.
Gesztes W, Schafer C, Young D, Fox J, Jiang J, Chen Y, Kuo HC, Mwamukonda KB, Dobi A, Burke AP, Moul JW, McLeod DG, Rosner IL, Petrovics G, Tan SH, Cullen J, Srivastava S, Sesterhenn IA. Gesztes W, et al. Among authors: mcleod dg. Sci Rep. 2022 Mar 30;12(1):5404. doi: 10.1038/s41598-022-08826-5. Sci Rep. 2022. PMID: 35354846 Free PMC article.
Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Kiebish MA, Tekumalla P, Ravipaty S, Dobi A, Srivastava S, Wu W, Patil S, Friss T, Klotz A, Srinivasan A, Cullen J, Rosner IL, Ali A, Laszlo S, Petrovic M, Fleshner N, Garren J, Miller G, Mahaveer Chand N, Rodrigues LO, Granger E, Kellogg MD, Luan S, Diamandis E, Akmaev VR, Sarangarajan R, Bountra C, Freedland SJ, McLeod DG, Narain NR. Kiebish MA, et al. Among authors: mcleod dg. Sci Rep. 2021 Jul 23;11(1):15052. doi: 10.1038/s41598-021-94438-4. Sci Rep. 2021. PMID: 34302010 Free PMC article.
Prognostic features of Annexin A2 expression in prostate cancer.
Tan SH, Young D, Chen Y, Kuo HC, Srinivasan A, Dobi A, Petrovics G, Cullen J, Mcleod DG, Rosner IL, Srivastava S, Sesterhenn IA. Tan SH, et al. Among authors: mcleod dg. Pathology. 2021 Feb;53(2):205-213. doi: 10.1016/j.pathol.2020.07.006. Epub 2020 Sep 20. Pathology. 2021. PMID: 32967771 Free PMC article.
Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data.
Higano CS, Armstrong AJ, Sartor O, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR. Higano CS, et al. Among authors: mcleod dg. Cancer. 2020 Jun 15;126(12):2935-2937. doi: 10.1002/cncr.32785. Epub 2020 Mar 10. Cancer. 2020. PMID: 32154908 Free PMC article. No abstract available.
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. Sartor O, et al. Among authors: mcleod dg. Prostate Cancer Prostatic Dis. 2020 Sep;23(3):517-526. doi: 10.1038/s41391-020-0213-7. Epub 2020 Feb 28. Prostate Cancer Prostatic Dis. 2020. PMID: 32111923 Free PMC article.
Multi-omic serum biomarkers for prognosis of disease progression in prostate cancer.
Kiebish MA, Cullen J, Mishra P, Ali A, Milliman E, Rodrigues LO, Chen EY, Tolstikov V, Zhang L, Panagopoulos K, Shah P, Chen Y, Petrovics G, Rosner IL, Sesterhenn IA, McLeod DG, Granger E, Sarangarajan R, Akmaev V, Srinivasan A, Srivastava S, Narain NR, Dobi A. Kiebish MA, et al. Among authors: mcleod dg. J Transl Med. 2020 Jan 7;18(1):10. doi: 10.1186/s12967-019-02185-y. J Transl Med. 2020. PMID: 31910880 Free PMC article.
Molecular profiling of radical prostatectomy tissue from patients with no sign of progression identifies ERG as the strongest independent predictor of recurrence.
Yan W, Jamal M, Tan SH, Song Y, Young D, Chen Y, Katta S, Ying K, Ravindranath L, Woodle T, Kohaar I, Cullen J, Kagan J, Srivastava S, Dobi A, McLeod DG, Rosner IL, Sesterhenn IA, Srinivasan A, Srivastava S, Petrovics G. Yan W, et al. Among authors: mcleod dg. Oncotarget. 2019 Nov 5;10(60):6466-6483. doi: 10.18632/oncotarget.27294. eCollection 2019 Nov 5. Oncotarget. 2019. PMID: 31741711 Free PMC article.
125 results